Drug intelligence / Profile preview

FI-RSV

Development stage: Preclinical
Lead developer: National Institute of Diagnostics
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

FI-RSV is a formalin-inactivated vaccine candidate developed by the National Institute of Diagnostics and Vaccine Development in Infectious Diseases (NIDVD) at Xiamen University for the prevention of Respiratory Syncytial Virus (RSV) infection. The vaccine is designed to induce protective immune responses against the virus by presenting inactivated viral particles to the immune system. Historically, formalin-inactivated RSV vaccines were associated with vaccine-enhanced respiratory disease (ERD) in clinical trials during the 1960s; however, modern research by NIDVD focuses on optimizing the inactivation process and formulation to ensure safety and efficacy. It is currently in the preclinical stage of development.

Other names: RSV inactivated vaccineFormalin-inactivated RSV vaccine

Beyond the preview

Go deeper on FI-RSV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FI-RSV.

Explore the full profile